Myriad Genetics (MYGN) Assets Average (2011 - 2026)

Myriad Genetics has disclosed Assets Average across 16 years of filings, most recently posting $690.2 million for Q1 2026.

• In Q1 2026, Assets Average fell 32.13% year-over-year to $690.2 million; the TTM figure through Mar 2026 stood at $690.2 million (down 32.13% YoY), while the FY2025 annual figure was $867.1 million, down 20.23% from the prior year.
• Assets Average slipped to $690.2 million in Q1 2026, from $717.4 million in the prior quarter.
• Over the last five years, Assets Average for MYGN reached as high as $1.3 billion in Q1 2022 and fell as low as $690.2 million in Q1 2026.
• The 5-year median for Assets Average is $1.1 billion (2024), against an average of $1.1 billion.
• Annual changes were most pronounced in 2023 — Assets Average retreated 3.55% — and 2025, when it tumbled 35.13%.
• A 5-year view of Assets Average shows it stood at $1.2 billion in 2022, then slipped by 4.77% to $1.1 billion in 2023, then fell by 8.13% to $1.1 billion in 2024, then sank by 31.97% to $717.4 million in 2025, then dropped by 3.79% to $690.2 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $690.2 million, $717.4 million, and $702.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.